Trial Profile

A phase III registrational trial of AP-301 for treatment of hyperphosphatemia

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 10 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs VS-505 (Primary)
Indications Hyperphosphataemia
Focus Registrational; Therapeutic Use
Sponsors Shanghai Alebund Pharmaceuticals

Most Recent Events

07 Jan 2025 According to an Alebund Pharmaceuticals media release, company announced the closing of RMB 550 million in Series C financing. This round of financing will support accelerating the conduct of its global pivotal study.
24 Aug 2022 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com